Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | MLNR | O43193 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.39 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14634674 | 1.00 | GPR119 (0.50) | GPR119EPHX2LMNAFFAR4MLNR | |
| SCHEMBL2551132 | 0.85 | GPR119 (0.72) | GPR119 | |
| SCHEMBL2551134 | 0.85 | GPR119 (0.72) | GPR119 | |
| SCHEMBL14634278 | 0.82 | GPR119 (0.71) | GPR119EPHX2MLNRHRH3 | |
| SCHEMBL14634277 | 0.82 | GPR119 (0.71) | GPR119EPHX2MLNRHRH3 | |
| SCHEMBL3348834 | 0.80 | EPHX2 (0.48) | EPHX2LMNAFFAR4HRH3FAAH | |
| SCHEMBL19610147 | 0.79 | EPHX2 (0.50) | EPHX2LMNAFFAR4HRH3SRD5A1 | |
| SCHEMBL5931838 | 0.79 | EPHX2 (0.65) | EPHX2LMNAFFAR4 | |
| SCHEMBL19610267 | 0.77 | FFAR4 (0.51) | EPHX2LMNAFFAR4FAAHSRD5A1 | |
| SCHEMBL3290157 | 0.76 | HRH3 (0.64) | GPR119EPHX2MLNRHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130023494-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023494-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | GPR119, SLC5A2, SLC5A1 | GPR119 1/4885EPHX2 2795/4885LMNA 4368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.